TAK
TAKEDA PHARMACEUTICAL CO LTDPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Aug 10 to Aug 19 ▼ 4 days of insider sells: $10.3M by 13 insiders, avg $17.21
- Aug 14 TAKEMATSU v. TAKEDA PHARMACEUTICALS U.S.A., INC.
- Sep 2 ▼ 1 insider sell $2.1M at $18.49
- Sep 14 ▲ Takeda announced FDA Priority Review acceptance of its NDA for zasoc…
- Sep 14 ▼ 1 insider sell $640.3K at $18.54
- Sep 24 Trial readout: Results Pending: Maribavir (Phase 3), Completed 64d ago
- Sep 30 ▲ Short interest falls 30.6% to 2.92M
- Oct 9 ▲ Ro Khanna bought $1,001 - $15,000, last disclosed Nov 9
- Oct 12 Trial readout: Results Pending: Dexlansoprazole (Phase 2), Completed 83d…
- Oct 23 Trial readout: Results Pending: TAK-788 (Phase 3), Completed 31d ago
- Oct 28 Trial readout: Results Pending: TAK-788 (Phase 2), completed 29d ago
- Nov 2 to Nov 4 ▼ 2 days of insider sells: $2.1M by 2 insiders, avg $20.90
Signal stack
Where each data set points today.
- InsidersBEARISH
13 insiders sold $15.2M.
- InstitutionsBULLISH
Q3 2026: 34 added (0 new), 11 trimmed or exited.
- Short sellersSTEADY
Short interest −6.8% to 3.07M shares. 1.0 days to cover, ≈0.1% of shares.
- TrendUPTREND
11% above its 50-day average. New closing high $21.59 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Capital Research Global Investors | ADD | $490.3M |
| JPMORGAN CHASE & CO | DOUBLED | $36.3M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $19.6M |
| LPL Financial LLC | TRIM | $6.6M |
| Nuveen, LLC | ADD | $5.8M |
| US BANCORP \DE\ | TRIM | $5.6M |
| RAYMOND JAMES FINANCIAL INC | TRIM | $5.4M |
| Russell Investments Group, Ltd. | ADD | $4.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action May 2023| Date | Firm | Rating |
|---|---|---|
| May 16, 2023 | TD Cowen MAINTAIN | Outperform |
| Apr 4, 2023 | TD Cowen MAINTAIN | Outperform |
| Mar 16, 2023 | B of A Securities UPGRADE | Buy |
| Jul 19, 2022 | Cowen & Co. UPGRADE | Outperform |
| Oct 7, 2021 | Morgan Stanley DOWNGRADE | Equal-Weight |
| Mar 11, 2020 | JP Morgan MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Platford Giles Richard President, IBU Nov 4, 2026 | SELL | $1.2M |
Bitetti Teresa Marie President, OBU Nov 2, 2026 | SELL | $973.7K |
Duprey Lauren Rusckowski Chief Transformation Officer Sep 14, 2026 | SELL | $640.3K |
Plump Andrew Stewart President, R&D Sep 2, 2026 | SELL | $2.1M |
Plump Andrew Stewart President, R&D Aug 19, 2026 | SELL | $363.3K |
Greenway Nicola Deidre Petal Chief Human Resources Officer Aug 18, 2026 | SELL | $235.1K |
Shannon Elaine Mary Pres., Global Supply & Quality Aug 11, 2026 | SELL | $357.4K |
Greenway Nicola Deidre Petal Chief Human Resources Officer Aug 10, 2026 | SELL | $588.7K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
18 filings · 1 bullish · 1 bearish · 1 mixed · 15 neutral- NEUTRAL CLUSTERNov 5, 2026
Two senior presidents of Takeda sold a combined $2.14M in open-market stock sales over three days…
The dollar amount is immaterial relative to Takeda's $65.6B market cap. No bearish signal. Monitor for any broader insider selling pattern or upcoming corporate events.
- NEUTRAL 144Oct 30, 2026
Giles Richard Platford, President of Takeda's International Business Unit, filed a Form 144 notice…
The filing is a standard advance notice for a planned insider sale tied to tax obligations on vested equity. No material impact expected; monitor for any acceleration of insider selling patterns or…
- NEUTRAL 144Oct 30, 2026
Teresa Bitetti, President of Takeda's Global Oncology Business Unit, filed a Form 144 to sell…
The sale is small relative to market cap and the insider's role is a business unit president, not the CEO/CFO. The prior tax-motivated sale pattern suggests this may be routine. Monitor for the…
- NEUTRAL 6-KOct 29, 2026
Takeda reported H1 FY2026 results with revenue of JPY 2,407.0 billion (+8.4% AER, -1.0% CER) and…
The constant-currency revenue decline (-1.0% CER) and flat core operating profit (+0.7% CER) indicate underlying business softness masked by FX tailwinds. Key catalysts to watch: FDA PDUFA for…
All TAK filing & press-release reports (18)
- CLUSTER reportNov 5, 2026
- 144 reportOct 30, 2026
- 144 reportOct 30, 2026
- 6-K reportOct 29, 2026
- 6-K reportOct 29, 2026
- 6-K reportSep 14, 2026
- CLUSTER reportAug 21, 2026
- CLUSTER reportAug 19, 2026
- COURT-RULING reportAug 14, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportAug 12, 2026
- 6-K reportJul 9, 2026
- 6-K reportJul 8, 2026
- 3 reportJul 6, 2026
- 6-K reportJun 29, 2026
- 6-K reportJun 24, 2026
- 6-K reportJun 24, 2026
- 6-K reportJun 24, 2026